MedTrace Logo

Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

NCT02138461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 211

Last updated 2014-09-25

Study results available
· View outcomes & findings →

Summary

This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

Conditions

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • MDbackline, LLC

    lead OTHER

Principal Investigators

  • John A. Hovanesian, MD · UCLA Jules Stein Eye Institute

  • Savak Teymoorian, MD · Harvard Eye Associates

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138461 on ClinicalTrials.gov